Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Operating Income (2016 - 2026)

Pharma-Bio Serv's Operating Income history spans 16 years, with the latest figure at -$94535.0 for Q1 2026.

  • For Q1 2026, Operating Income fell 2.54% year-over-year to -$94535.0; the TTM value through Jan 2026 reached -$640006.0, up 32.02%, while the annual FY2025 figure was -$637662.0, 50.48% up from the prior year.
  • Operating Income reached -$94535.0 in Q1 2026 per PBSV's latest filing, up from -$133272.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $460466.0 in Q3 2023 to a low of -$438300.0 in Q1 2024.
  • Average Operating Income over 5 years is $16033.6, with a median of -$92191.0 recorded in 2025.
  • Peak YoY movement for Operating Income: soared 103.52% in 2022, then plummeted 233.37% in 2024.
  • A 5-year view of Operating Income shows it stood at $168962.0 in 2022, then plummeted by 130.64% to -$51765.0 in 2023, then tumbled by 197.75% to -$154130.0 in 2024, then grew by 13.53% to -$133272.0 in 2025, then rose by 29.07% to -$94535.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Operating Income are -$94535.0 (Q1 2026), -$133272.0 (Q4 2025), and -$313877.0 (Q3 2025).